2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · IEX Real-Time Price · USD
3.860
-0.190 (-4.69%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Company Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
2seventy bio, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | William D. Baird III, M.B.A. |
Contact Details
Address: 60 Binney Street Cambridge, Massachusetts 02210 United States | |
| Phone | 339-499-9300 |
| Website | 2seventybio.com |
Stock Details
| Ticker Symbol | TSVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860782 |
| CUSIP Number | 901384107 |
| ISIN Number | US9013841070 |
| Employer ID | 86-3658454 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William D. Baird III, M.B.A. | Chief Executive Officer |
| Nick Leschly | President and Director |
| Dr. Philip D. Gregory D. Phil., DPHIL | Chief Scientific Officer |
| Vicki Eatwell | Chief Financial Officer |
| Jessica Snow | Senior Vice President of Quality and Head of Operations |
| Susan Abu-Absi Ph.D. | Chief Technology Officer |
| Teresa L. Jurgensen J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Kerri Jensen | Head of People and Culture |
| Jenn Snyder | Senior Vice President of Corporate Affairs |
| Dr. Steven Bernstein M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 8-K | Current Report |